Cytonet GmbH & Co. KG, of Weinheim, Germany, said interim data on its liver cell therapy treatment presented at the Society for Inherited Metabolic Disorders meeting in Pacific Grove, Calif., showed that pediatric patients with urea cycle disorders (UCDs) treated with the therapy had advantages in parameters such as event-free survival time or incidence of moderate or severe hyperammonemic events.